StreetInsider.com News Articles

Lexicon drug shows cardiac and platelet effects in preclinical studies

Wed, 21 Oct 2026 08:32:41 -0400

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced findings from two preclinical studies examining the biological effects of sotagliflozin, its dual SGLT1 and SGLT2 inhibitor, in cardiovascular disease models.

The first study, published in the Journal of Molecular and Cellular Cardiology Plus, used a mouse model of hypertrophic cardiomyopathy (HCM) and found that sotagliflozin normalized diastolic function, reversed cardiac hypertrophy progression, reduced cardiac fibrosis, and reduced oxidative stress while upregulating mitochondrial gene sets associated with energy production in heart tissue.

The second study, published in the Journal of Clinical Investigation, found that sotagliflozin reduced platelet activation and thrombus formation in ex vivo human blood and

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease

Wed, 21 Oct 2026 08:30:00 -0400

-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy --

-- Second preclinical study shows inhibitory effects of sotagliflozin on platelet activity and thrombus formation --

-- Findings underscore differentiated biology associated with dual SGLT1 and SGLT 2 inhibition --

THE WOODLANDS, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today highlighted findings from two newly reported preclinical studies that provide additional insight into the biological effects of sotagliflozin, Lexicon's

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease

Wed, 21 Oct 2026 08:30:00 -0400

-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy --

-- Second preclinical study shows inhibitory effects of sotagliflozin on platelet activity and thrombus formation --

-- Findings underscore differentiated biology associated with dual SGLT1 and SGLT 2 inhibition --

Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM

Mon, 28 Sep 2026 11:42:57 -0400

Investing.com -- Shares of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) rallied over 13% in Monday morning trading following a bullish initiation of coverage from Wall Street research firm Cantor Fitzgerald. The broker set an Overweight rating and an $8.00 price target on the biopharmaceutical company, reflecting substantial upside potential driven by the company’s ongoing late-stage cardiovascular research program.

The primary catalyst behind Cantor Fitzgerald’s positive thesis is sotagliflozin, Lexicon’s dual SGLT1/2 inhibitor currently being evaluated in the pivotal Phase 3 SONATA-HCM trial for hypertrophic cardiomyopathy (HCM). Cantor Fitzgerald analyst Steve Seedhouse highlighted that

Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM

Mon, 28 Sep 2026 11:42:57 -0400

Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight

Mon, 28 Sep 2026 07:01:25 -0400

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) with a Overweight rating, PT $8.00.

The analyst comments "We are initiating coverage of LXRX at Overweight with a 12-mo $8 price target based on our view that the ongoing Phase 3 SONATA-HCM trial of SGLT1/2 inhibitor sotagliflozin ("sota") in hypertrophic cardiomyopathy (HCM) will work. SONATA-HCM is fully enrolled; data expected 1Q27. You read that correctly ‒ legacy SGLT1/2 inhibitor sotagliflozin (approved for heart failure as Inpefa, although commercialization has since been deprioritized) is now approaching a pivotal trial readout in 1Q27 for HCM, and the mechanistic rationale and

Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight

Mon, 28 Sep 2026 07:01:25 -0400

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) with a Overweight rating, PT $8.00.

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

Tue, 01 Sep 2026 16:05:00 -0400

THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY:

Citi 2026 Biopharma Back to School Conference
September 9, 2026, 11:20–11:55 AM (Eastern Time)

2026 Cantor Global Healthcare Conference
September 10, 2026, 3:20–3:50 PM (Eastern Time)

H.C. Wainwright 28th Annual Global Investment Conference
September 14, 2026, 9:00–9:30 AM (Eastern Time)

The live events and replays of the presentations can be accessed via the Events page on the company’s website at

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

Tue, 01 Sep 2026 16:05:00 -0400

Citi 2026 Biopharma Back to School Conference
September 9, 2026, 11:20–11:55 AM (Eastern Time)

2026 Cantor Global Healthcare Conference
September 10, 2026, 3:20–3:50 PM (Eastern Time)

H.C. Wainwright 28th Annual Global Investment Conference
September 14, 2026, 9:00–9:30 AM (Eastern Time)

The live events and replays of the presentations can be accessed via the Events page on the company’s website at

Lexicon sotagliflozin shows consistent results across blood pressure levels

Mon, 31 Aug 2026 08:32:12 -0400

Lexicon Pharmaceuticals (NASDAQ: LXRX) announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial, showing that sotagliflozin's effects were consistent across baseline systolic blood pressure levels in patients recently hospitalized for worsening heart failure.

The findings were presented at ESC Congress 2026 in Munich, Germany, and simultaneously published in JACC: Heart Failure.

The analysis, based on data from 1,222 patients with type 2 diabetes, showed that sotagliflozin reduced cardiovascular death and heart failure-related events regardless of baseline systolic blood pressure. Among patients with a baseline systolic blood pressure below 110 mmHg (n=201), those receiving sotagliflozin experienced a reduction in

Lexicon sotagliflozin shows consistent results across blood pressure levels

Mon, 31 Aug 2026 08:32:12 -0400

The findings were presented at ESC Congress 2026 in Munich, Germany, and simultaneously published in JACC: Heart Failure.

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Mon, 31 Aug 2026 08:30:00 -0400

Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure

THE WOODLANDS, Texas, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety of sotagliflozin across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure.

The data, which were presented yesterday at ESC Congress 2026 in Munich, Germany and simultaneously published in JACC: Heart Failure¹, demonstrated that the results of sotagliflozin treatment

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Mon, 31 Aug 2026 08:30:00 -0400

Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure

The data, which were presented yesterday at ESC Congress 2026 in Munich, Germany and simultaneously published in JACC: Heart Failure¹, demonstrated that the results of sotagliflozin treatment

Lexicon earns third $10M milestone from Novo Nordisk for LX9851

Mon, 24 Aug 2026 08:30:17 -0400

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S after achieving a patient dosing milestone in the Phase 1 clinical development program for LX9851, an oral small molecule inhibitor of ACSL5 being developed for obesity and associated metabolic disorders.

With this payment, Lexicon has now received $75 million of a potential $1 billion in upfront, development, regulatory, and commercial milestone payments available under its collaboration with Novo Nordisk. Lexicon is also entitled to tiered royalties on future net sales of LX9851.

Novo Nordisk obtained an exclusive worldwide license to develop, manufacture,

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Mon, 24 Aug 2026 08:30:00 -0400

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders

Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales

THE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achievement of a key patient dosing milestone in the ongoing Phase 1 clinical development program for

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Mon, 24 Aug 2026 08:30:00 -0400

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders

Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales

Form EFFECT LEXICON PHARMACEUTICALS,

Mon, 17 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260817/26934368.html

Form EFFECT LEXICON PHARMACEUTICALS,

Mon, 17 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260817/26934368.html

Form S-3 LEXICON PHARMACEUTICALS,

Thu, 06 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26885439.html

Form S-3 LEXICON PHARMACEUTICALS,

Thu, 06 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26885439.html

Form S-8 LEXICON PHARMACEUTICALS,

Thu, 06 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26884810.html

Form S-8 LEXICON PHARMACEUTICALS,

Thu, 06 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26884810.html

Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883723.html

Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883723.html

Form SCHEDULE 13G/A LEXICON PHARMACEUTICALS, Filed by: FMR LLC

Thu, 06 Aug 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26881239.html